Kalbe Farma Tbk PT banner
Financial profile · Q3 FY2026

Diversified healthcare businesses combine steady growth and cash generation

Kalbe has delivered multi-year sales growth across pharmaceuticals, consumer health, nutritionals, and distribution, with operating profitability that has not widened consistently. It generally generates free cash flow after investment, though working-capital swings affect cash conversion; reported cash has exceeded borrowings.

What is developing

The latest quarter showed year-over-year growth in sales and operating income, while the trailing-year operating margin remained slightly below its year-earlier level. This is a positive quarterly movement, not yet evidence of a lasting change in the company’s financial model.

What matters next

Whether gross margin stabilizes while recent SG&A leverage persists, clarifying if the quarterly operating-margin improvement is durable.

IDR
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
(731.8B) (751.4B) (835.1B) (818.6B) (592.2B) (965.7B) (1.2T) (985.6B) (910.7B) (1T)
(8.1T) (8.7T) (8.3T) (8.8T) (8.2T) (9.2T) (9.8T) (10.3T) (10.4T) (12T)
2.2T 2T 2.8T 2.5T 4.2T 2.8T 1.3T 2.9T 4.8T 3.3T
(1.1T) (1.2T) (1.4T) (2T) (1.1T) (1T) (870.1B) (1.2T) (1.3T) (809.9B)
84B 121.9B 83.2B 82.4B 167B (55.1B) (500.3B) 38.2B 3B 10B
(1T) (1.1T) (1.3T) (1.9T) (951.2B) (1.1T) (1.4T) (1.1T) (1.2T) (799.9B)
— — — — (2.1B) 0 (1T) 0 (457.4B) (842.1B)
(84.3B) 72.4B 41.8B 416B 235.1B (533.2B) 319.9B (573.1B) (91.9B) (295.1B)
(890.6B) (1T) (1.2T) (1.2T) (1.3T) (1.4T) (1.7T) (1.8T) (1.5T) (1.7T)
33.5B (17.5B) (9.6B) 95.9B (80.5B) 1.2T (36.1B) (55.9B) (62B) (43.3B)
(941.4B) (976.4B) (1.1T) (706.9B) (1.1T) (745.2B) (2.4T) (2.4T) (2.1T) (2.9T)
(7.2B) 8.7B 27B (51.8B) 51.3B (16.4B) 237.8B (40.1B) 44.9B 6.7B
196.3B (73B) 368.2B (156.3B) 2.2T 1T (2.3T) (717.3B) 1.5T (391.9B)
1.1T 772.8B 1.4T 520B 3.1T 1.8T 401.8B 1.7T 3.5T 2.5T